Navigation Links
Starpharma Announces $15.6 million Capital Raising
Date:11/18/2009

ting extension to the development program of VivaGel®. Bacterial vaginosis is the most common vaginal infection worldwide with more than 21 million women in the US alone suffering from the infection," said Dr Fairley.

Starpharma already has a significant licensing deal with SSL (owners of Durex® brand) for use of VivaGel® as a condom coating, NIH funded development programs for VivaGel® for the prevention of viral sexually transmitted infections, programs focused on drug delivery partnered with Elanco (Eli Lilly) and Stiefel (GSK), and a program for modifying pesticides with a multi-billion dollar US agrochemical company.

As the shares issued via the private placement fall within the 15% threshold permitted by the ASX Listing Rules, shareholder approval is not required.

About Starpharma

Starpharma Holdings Limited (ASX: SPL; OTCQX: SPHRY) is a world leader in the development of dendrimer technology for pharmaceutical, life-science and other applications. SPL has two operating companies, Starpharma Pty Ltd in Melbourne, Australia and DNT, Inc in the USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents through licence arrangements with partners including Siemens and Merck KgA.

The Company's lead pharmaceutical development product is VivaGel® (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes. In September 2008 Starpharma signed a full licence agreement with SSL International plc (LSE: SSL) to develop a VivaGel® coated condom.

    For further information:

    Media
    Buchan Consulting
    Kyahn Williamson
    Tel:  +61 3 9866 4722
    Mob: +61 401 018 828
    kwilliamson@bcg.com.au

    Ellie Papathanasiou
    Tel:  +61 3 9866 4722
 
'/>"/>
SOURCE Starpharma Holdings Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quest Diagnostics Announces Pricing of Tender Offer for Any and All of Certain of its Outstanding Notes
2. Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results
3. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
4. China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results
5. L.A. Zoo Announces Successful Cancer Treatment of Rhinoceros With Electronic Brachytherapy
6. Personalized Pharmaceutical Systems Announces Sale of Angioedema Clinical Prediction Guide to Viropharma Incorporated
7. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
8. AMD LASERS Announces the Addition of Bart Waclawik, New Chief Operating Officer
9. Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants
10. Cardo Medical, Inc. Announces Closing of $6.2 Million Private Placement
11. Misonix Announces New Distribution Agreement for Argentina
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... , Sept. 15, 2014 /CNW/ - Health Minister Rona ... will make available for donation over $2.5 million in personal ... aid in the global response to the Ebola outbreak in ... WHO reported a shortage of equipment in the affected countries ... by front-line workers in the affected countries. ...
(Date:9/15/2014)... 15, 2014 /PRNewswire/ -  Pivotal Therapeutics Inc. (OTCQX:PVTTF; ... company with a focus on Omega-3 therapies for ... the Board of Directors approved the granting of ... the close of business on Friday, September 12, ... common shares of the Company were granted in ...
(Date:9/15/2014)... /PRNewswire-iReach/ -- Asthma is a chronic inflammatory lung ... most commonly starts in childhood. It is a ... airways, leading to airflow limitation and airway hyper-responsiveness ... endogenous and exogenous irritants. Exposure to irritants instigates ... the airways, tightening of the respiratory muscles, and ...
Breaking Medicine Technology:Canada offers essential protective equipment to help stop the spread of Ebola in West Africa 2Canada offers essential protective equipment to help stop the spread of Ebola in West Africa 3Pivotal Therapeutics Grants Incentive Stock Options 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 3Asthma Market to Reach 161.02 million Cases in 10MM by 2023 4Asthma Market to Reach 161.02 million Cases in 10MM by 2023 5
... DIEGO, Feb. 29, 2012  Polaris Group (Polaris) today announced ... Phase 1 clinical trial evaluating its lead cancer therapeutic, ... emphasis on leukemia, lymphoma and sarcoma cancers. These three ... in the pediatric population. Patients with advanced ...
... Md., Feb. 29, 2012  Northwest Biotherapeutics (OTC.BB: NWBO) (NW ... Ph.D., MA, MBA, will be presenting at the Cancer ... pm ET on Wednesday, February 29, 2012, in Boston, Massachusetts ... (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ) ...
Cached Medicine Technology:Polaris Group Doses First Patient in Phase 1 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 in Pediatric Patients with Emphasis on Leukemia, Lymphoma and Sarcoma 2Polaris Group Doses First Patient in Phase 1 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 in Pediatric Patients with Emphasis on Leukemia, Lymphoma and Sarcoma 3NW Bio to Present at the Cancer Immunotherapy Summit 2NW Bio to Present at the Cancer Immunotherapy Summit 3NW Bio to Present at the Cancer Immunotherapy Summit 4
(Date:9/16/2014)... 16, 2014 Wholelifeinsurancecompanies.org has released a ... life insurance with a bad heart condition. , Clients ... affordable life insurance if they compare quotes. Most agencies ... decision depend on the actual and past medical condition. ... caused several heart attacks in the past, his or ...
(Date:9/16/2014)... comparison of five-year sexual function outcomes, as ... radiotherapy (EBRT) versus combination EBRT plus brachytherapy, ... therapy makes cure possible without compromising long-term ... at the American Society for Radiation Oncology,s ... study examined the patient-reported outcomes of 91 ...
(Date:9/16/2014)... than any other workplace incident, a statistic that transport ... conference being hosted by QUT,s Centre for Accident Research ... Safety in Transport Conference (OSIT) to be held on ... together experts from all facets of transport safety including ... and safety. , CARRS-Q research fellow Darren Wishart said ...
(Date:9/16/2014)... have developed a new cocktail that is highly ... pluripotent stem cells. , Regenerative medicine is a ... lost or damaged cells, tissues or organs through ... embryos can trigger ethical concerns, a good solution ... state using a combination of reprogramming factors. ...
(Date:9/16/2014)... 2014 An experimental positron emission tomography ... while a person is still alive, according to a ... at Mount Sinai, and at Molecular Neuroimaging (MNI) LLC ... journal Translational Psychiatry. , Specifically, the study results suggest ... is designed to latch onto a protein called tau ...
Breaking Medicine News(10 mins):Health News:No Exam Life Insurance for Clients Who Have a Bad Heart Condition! 2Health News:Prostate cancer patients surveyed 5 years after vessel-sparing RT report preserved sexual function 2Health News:Prostate cancer patients surveyed 5 years after vessel-sparing RT report preserved sexual function 3Health News:CARRS-Q Host International Transport Safety Conference 2Health News:Scientists create therapy-grade stem cells using new cocktail to reprogram adult cells 2Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 2Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 3Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 4
... His Royal Highness, The Duke of York,was the ... to mark the United States,launch of UK-based specialty ... US product, Sancuso, is currently under,consideration for licensing ... (Photo: http://www.newscom.com/cgi-bin/prnh/20080214/NYTH111 ), Prince Andrew ...
... validity of self-reported tobacco use in research, care , , ... more likely than younger ones to deny they smoke ... That,s the conclusion of a study that analyzed data ... took part in the third National Health and Nutrition ...
... Dividend, ACTON, Mass., Feb. 14 Psychemedics,Corporation (Amex: ... results for the period ended December 31, 2007, which ... The Company,also announced a quarterly dividend of $0.15 per ... 2008 to be paid on March 21, 2008.,This will ...
... Weight Watchers,International, Inc. (NYSE: WTW ) today announced results ... 2007., Fourth Quarter 2007 Results, For the fourth ... $344.0 million. Fully diluted earnings per share in the fourth,quarter ... period. The prior,year included a benefit of $0.06 per share ...
... N.J., Feb. 14 TeamStaff, Inc.,(Nasdaq: TSTF ), ... announced its financial results for the first,quarter ended December ... months ended December 31, 2007 was,$0.1 million as compared ... last year. Income from continuing operations was $0.04 million ...
... 14 /PRNewswire-USNewswire/ - The Foundation,for Taxpayer and Consumer ... HMO,regulator calling for swift action to end Blue ... medical records for any,excuse to dump patients who ... the Los Angeles Times on Wednesday,that the practice ...
Cached Medicine News:Health News:His Royal Highness The Duke of York Helps Launch UK-Based Pharmaceutical Company, ProStrakan, in the United States 2Health News:His Royal Highness The Duke of York Helps Launch UK-Based Pharmaceutical Company, ProStrakan, in the United States 3Health News:Older Smokers More Likely to Deny Habit 2Health News:Psychemedics Corporation Announces Year End Results Record Annual and Quarterly Revenue 2Health News:Psychemedics Corporation Announces Year End Results Record Annual and Quarterly Revenue 3Health News:Psychemedics Corporation Announces Year End Results Record Annual and Quarterly Revenue 4Health News:Psychemedics Corporation Announces Year End Results Record Annual and Quarterly Revenue 5Health News:Psychemedics Corporation Announces Year End Results Record Annual and Quarterly Revenue 6Health News:Weight Watchers Announces Fourth Quarter and Full Year 2007 Results 2Health News:Weight Watchers Announces Fourth Quarter and Full Year 2007 Results 3Health News:Weight Watchers Announces Fourth Quarter and Full Year 2007 Results 4Health News:Weight Watchers Announces Fourth Quarter and Full Year 2007 Results 5Health News:Weight Watchers Announces Fourth Quarter and Full Year 2007 Results 6Health News:Weight Watchers Announces Fourth Quarter and Full Year 2007 Results 7Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 2Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 3Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 4Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 5Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 6Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 7Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 8Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 9Health News:FTCR: Gov. Schwarzenegger Must Follow Through on Call to Ban Blue Cross From Using Doctors as Double-Agents to Dump Sick Patients 2
... three-dimensional VCS technology, providing ... efficiency in white cell ... With its reputation for ... is an affordable solution ...
Creatinine Test Kit (enzymatic), Wavelength: 340 nm. Linear range: up to 20 mg/dL....
For the quantitative determination of Creatine Kinase in serum....
For the qualitative determination of magnesium in serum....
Medicine Products: